Lepu Medical Technology Co (300003) Q1 2025 earnings summary

Executive summary

• Revenue for Q1 2025 was ¥1.74 billion, down 9.67% year-over-year, but up 31.75% sequentially from Q4 2024.

• Net profit attributable to shareholders was ¥378.54 million, a 21.44% decrease year-over-year.

• Cash flow from operating activities increased 196.09% year-over-year to ¥419.02 million.

Financial highlights

• Gross margin declined by 2.86 percentage points due to centralized procurement and drug policy impacts.

• Basic EPS was ¥0.2053, down 20.86% year-over-year.

• Total assets at quarter-end were ¥25.23 billion, up 2.69% from year-end 2024.

• Owner's equity attributable to shareholders rose 2.73% to ¥15.62 billion.

Outlook and guidance

• Revenue structure is stabilizing with retail channel inventory clearance nearly complete.

• Non-atorvastatin and clopidogrel products are increasing in revenue share.